Targeted therapies and radiotherapy;Thérapeutiques ciblées et radiothérapie

Bulletin du Cancer

Volumn 92, Issue 12, 2005, Pages 1085-1092

  Hennequin, Christophe ^a,b   Giocanti, Nicole ^b   Favaudon, Vincent ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Angiogenesis; Cell cycle; EGF receptor; Farnesyltransferase inhibitors; Radiotherapy; Targeted therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CETUXIMAB; CYTOSTATIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; L 788123; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PROTEIN FARNESYLTRANSFERASE INHIBITOR; STAUROSPORINE; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; HYPOKALEMIA; HYPONATREMIA; IONIZING RADIATION; NONHUMAN; QT PROLONGATION; RADIOSENSITIZATION; REVIEW; SIDE EFFECT; SKIN TOXICITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL CYCLE; COMBINED MODALITY THERAPY; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 30544440756     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Hanahan D, Weinberg R. The hallmarks of cancer. Cell 2000; 100: 57-70.
2. Eriksen J, Steiniche T, Askaa J, Overgaard J. The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 2004; 58: 561-6.
3. Chua D, Nicholls J, Sham J, Au G. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2004; 59: 11-20.
4. Ang K, Berkey B, Tu X, Zhang H, Katz R, Hammond E, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62: 7350-6.
5. Gibson M, Abraham S, Wu T, Burtness B, Heitmiller R, Heath E, et al. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 2003; 9: 6461-8.
6. Akimoto T, Hunter N, Buchmiller L, Mason K, Kian Ang K, Milas L. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999; 5: 2884-90.
7. Withers HR, Taylor JM, Maciejesky B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988; 27: 131-46.
8. Fowler J, Lindstrom M. Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 1992; 23: 457-67.
9. Schmidt-Ullrich R, Contessa J, Dent P, Mikkelsen R, Valerie K, Reardon D, et al. Molecular mechanisms of radiation-induced accelerated repopulation. Radiat Oncol Investig 1999; 7: 321-30.
10. Schmidt-Ullrich R, Mikkelsen R, Dent P, Todd D, Valerie K, Kavanagh B, et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 1997; 15: 1191-7.
11. Petersen C, Eicheler W, Frommel A, Krause M, Balschukat S, Zips D, et al. Proliferation and micromilieu during fractionated irradiation of human FaDu squamous cell carcinoma in nude mice. Int J Radiat Biol 2003; 79: 469-77.
12. Schmidt-Ullrich R, Valerie K, Fogleman P, Walters J. Radiation-induced autophosphorylation of epidermal growth factor receptor in malignant mammary and squamous epithelial cells. Radiat Res 1996; 145: 81-5.
13. Giocanti N, Hennequin C, Rouillard D, DeFrance R, Favaudon V. Additive interaction of gefitinib ('Iressa', ZD1839) and ionising radiation in human tumour cells in vitro. Br J Cancer 2004; 13: 2026-33.
14. Baumann M, Krause M. Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radioth Oncol 2004; 72: 257-66.
15. Nasu S, Ang K, Fan Z, Milas L. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys 2001; 51: 474-7.
16. Huang S, Harari P. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinoma: inhibition of damage repair, cell cycle kinetics and tumour angiogenesis. Clin Cancer Res 2000; 6: 2166-74.
17. Krause M, Schütze C, Petersen C, Pimentel N, Hessel F, Harstrick A, et al. Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDU hSCC. Radioth Oncol 2005; 74: 109-15.
18. Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000; 6: 701-8.
19. Robert F, Ezechiel M, Spencer S, Meredith R, Bonner J, Khazaeli M, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19: 3234-43.
20. Bonner J, Giralt J, Harari P, Cohen R, Jones C, Sur R, et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation with or without cetuximab. Proc Am Soc Clin Oncol 2004; 22; (abstr 5507).
21. Bonner J, Harari P, Giralt J, Baselga J, Shin D, Cohen R, et al. Improved preservation of larynx with the addition of cetuximab to radiation for cancers of the larynx and hypopharynx. Proc Am Soc Clin Oncol 2005; 53; (abstr 5533).
22. Shintani S, Li C, Mihara M, Terakado N, Yano J, Nakashiro K, et al. Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer. Int J Cancer 2003; 107: 1030-7.
23. Huang S, Li J, Armstrong E, Harari P. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 ('Iressa'). Cancer Res 2002 2002: 4300-6.
24. Williams K, Telfer B, Stratford I, Wedge S. ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 2002; 86: 1157-61.
25. Solomon B, Hagekyriakou J, Trivett M, Stacker S, McArthur G, Cullinane C. EGFR blockade with ZD1839 ('Iressa') potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2003; 55: 713-23.
26. Bianco C, Tortora G, Veneziani B, Caputo R, Damiano V, Troiani T, et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor. Clin Cancer Res 2002; 8: 3250-8.
27. Magne N, Fischel J, Dubreuil A, Formento P, Marcié S, Lagrange J, et al. Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 2002; 86: 818-27.
28. Krause M, Hessel F, Zips D, Hilberg F, Baumann M. Adjuvant inhibition of the epidermal growth factor receptor after fractionated irradiation of FaDu human squamous cell carcinoma. Radioth Oncol 2004; 72: 95-101.
29. Cohen E, Haraf D, Stenson K, Blair E, Brockstein B, Mauer A, et al. Integration of gefitinib (G), into a concurrent chemoradiation (CRT) regimen followed by G adjuvant therapy in patients with locally advanced head and neck cancer (HCN): a phase II trial. Proc Am Soc Clin Oncol 2005; (abstr. 5506).
30. Lynch T, Bell D, Sordella R, Gurubhagavatula S, Okimoto R, Brannigan B, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
31. Carmeliet P, Jain R. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
32. Scappaticci F. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002; 20: 3906-27.
33. Eberhard A, Kahlert S, Goede V. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000; 60: 1388-93.
34. O'Reilly M. The combination of antiangiogenic therapy with other modalities. Cancer J 2002; 8(suppl. 1): S89-99.
35. Camphausen K, Moses M, Beecken W, Khan M, Folkman J, O'Reilly M. Radiation therapy to a primary rumor accelerates metastatic growth in mice. Cancer Res 2001; 61: 2207-11.
36. Hartford A, Gohongi T, Fukumura D, Jain R. Irradiation of a primary tumor, unlike surgical removal, enhances angiogenesis suppression at a distal site: potential role of host-tumor interaction. Cancer Res 2000; 60: 2128-31.
37. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, et al. Combined effects of angiostatin and ionizing radiation in antitumor therapy. Nature 1998; 394: 287-91.
38. Ferrara N, Gerber H, LeCouter J. The biology of VEGF and its receptor. Nat Med 2003; 9: 669-76.
39. Gorski DH, Beckett M, Jaskowiak N, Calvin D, Mauceri H, Salloum R, et al. Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999; 59: 3374-8.
40. Geng E, Donnelly E, McMahon G, Lin P, Sierra-Rivera E, Oshinka H, et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 2001; 61: 2413-9.
41. Kozin S, Boucher Y, Hicklin D, Bohlen P, Jain R, Suit H. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 2001; 61: 39-44.
42. Lee C, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response inder normoxic and hypoxic conditions. Cancer Res 2000; 60: 5565-70.
43. Zips D, Hessel F, Krause M, Schieffer Y, Hoinkis C, Thames H, et al. Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice. Int J Radiat Oncol Biol Phys 2005; 61: 908-14.
44. Ning S, Laird D, Cherrington J, Knox S. The antiangiogenic agents SU5416 et SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res 2002; 157: 45-51.
45. Lu B, Gene Musiek A, Tan J, Cao C, Donnelly E, et al. Broad spectrum receptor tyrosin kinase inhibitor, SU6668, sensitizes radiation via targeting survival pathway of vascular endothelium. Int J Radiat Oncol Biol Phys 2004; 58: 844-50.
46. Abdollahi A, Lipson K, Han X, Krempien R, Trinh T, Weber K, et al. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res 2003; 63: 3755-63.
47. Griffin R, Williams B, Wild R, Cherrington J, Park H, Song C. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances radiation response. Cancer Res 2002; 62: 1702-6.
48. Murata R, Siemann D, Overgaard J, Horsman M. Interaction between combrestatin A-4 disodium phosphate and radiation in murine tumors. Radioth Oncol 2001; 60: 155-61.
49. Landuyt W, Ahmed B, Nuyts S, Theys J, de Beeck M, Rijnders A, et al. In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis. Int J Radiat Oncol Biol Phys 2001; 49: 443-50.
50. Siemann D, Rojiani A. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002; 53: 164-71.
51. Murata R, Nishimura Y, Hiraoka M. An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int J Radiat Oncol Biol Phys 1997; 37: 1107-13.
52. Teicher B, Holden S, Dupuis N, Kakeji Y, Ikebe M, Emi Y, et al. Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Res Treat 1995; 36: 227-36.
53. Lund E, Bastholm L, Kristjansen P. Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts. Clin Cancer Res 2000; 6: 971-8.
54. Wachsberger P, Burd R, Dicker A. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring the mechanisms of interaction. Clin Cancer Res 2003; 9: 1957-71.
55. Teicher B, Emi Y, Kakeji Y. TNP-470/minocyclin/cytotoxic therapy: a systems approach to cancer therapy. Eur J Cancer 1996; 32: 2461-6.
56. Winkler F, Kozin S, Tong R, Chae S, Booth M, Garkavtsev I, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004; 6: 553-63.
57. Hansen-Algenstaedt N, Stoll B, Padera T, Dolmans D, Hicklin D, Fukumura D, et al. Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy. Cancer Res 2000; 60: 4556-60.
58. Jain R. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
59. Willett C, Boucher Y, di Tomaso E, Duda D, Munn L, Tong R, et al. Direct evidence that the VEGF-antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-7.
60. Moeller B, Cao Y, Vujaskovic Z, Li C, Haroon Z, Dewhirst M. The relationship between hypoxia and angiogenesis. Semin Radiat Oncol 2004; 14: 215-21.
61. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300: 1155-9.
62. McKenna W, Weiss M, Bakanauskas V, Sandler H, Kelstein M, Braglow J, et al. The role of the H-ras oncogene in radiation resistance and metastasis. Int J Radiat Oncol Biol Phys 1990; 18: 849-59.
63. Sklar M. The ras oncogene increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science 1988; 239: 645-7.
64. McKenna W, Bernhard E, Markiewicz D, Rudoltz M, Maity A, Muschel R. Regulation of radiation-induced apoptosis in oncogene-transfected fibroblasts: influence of H-ras on the G2 delay. Oncogene 1996; 12: 237-45.
65. Bernhard E, McKenna W, Muschel R. Radiosensitivity and the cell cycle. Cancer J Sci Am 1999; 5: 194-204.
66. Brunner T, Hahn S, Gupta A, Muschel R, McKenna W, Bernhard E. Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. Cancer Res 2003; 63: 5656-68.
67. Bernhard E, McKenna W, Hamilton A, Sebti S, Qian Y, Wu J, et al. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutation sof ras oncogenes. Cancer Res 1998; 58: 1754-61.
68. Bernhard E, Kao G, Cox A, Sebti S, Hamilton A, Muschel R, et al. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras transformed rat embryo fibroblasts. Cancer Res 1996; 56: 1727-30.
69. Cohen-Jonathan E, Muschel R, McKenna W, Evans S, Cerniglia G, Mick R, et al. Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated H-Ras. Radiat Res 2000; 154: 125-32.
70. Cohen-Jonathan E, Evans S, Koch C, Muschel R, McKenna W, Wu J, et al. The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras. Cancer Res 2001; 61: 2289-93.
71. Hahn S, Bernhard E, Regine W, Mohiuddin M, Haller D, Stevenson J, et al. A phase I trial of the farnesyltransferase inhibitor L-778, 123 and radiotherapy for locally advanced lung and head and neck cancer. Clin Cancer Res 2002; 8: 1065-72.
72. Raju U, Nakata E, Mason K, Ang K, Milas L. Flavoperidol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells. Cancer Res 2003; 63: 3203-7.
73. Hennequin C, Favaudon V. Biological basis for chemo-radiotherapy interactions. Eur J Cancer 2002; 38: 223-30.
74. Maggiorella L, Deutsch E, Frascogna V, Chavaudra N, Jeanson L, Milliat F, et al. Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo. Cancer Res 2003; 63: 2513-7.